CoChat

Toward Repurposing Ciclopirox as an Antibiotic against Drug-Resistant Acinetobacter baumannii, Escherichia coli, and Klebsiella pneumoniae

Open access

The DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.

Abstract

Antibiotic-resistant infections caused by gram-negative bacteria are a major healthcare concern. Repurposing drugs circumvents the time and money limitations associated with developing new antimicrobial agents needed to combat these antibiotic-resistant infections. Here we identified the off-patent antifungal agent, ciclopirox, as a candidate to repurpose for antibiotic use. To test the efficacy of ciclopirox against antibiotic-resistant pathogens, we used a curated collection of Acinetobacter baumannii, Escherichia coli, and Klebsiella pneumoniae clinical isolates that are representative of known antibiotic resistance phenotypes. We found that ciclopirox, at 5-15 µg/ml concentrations, inhibited bacterial growth regardless of the antibiotic resistance status. At these same concentrations, ciclopirox reduced growth of Pseudomonas aeruginosa clinical isolates, but some of these pathogens required higher ciclopirox concentrations to completely block growth. To determine how ciclopirox inhibits bacterial growth, we performed an overexpression screen in E. coli. This screen revealed that galE, which encodes UDP-glucose 4-epimerase, rescued bacterial growth at otherwise restrictive ciclopirox concentrations. We found that ciclopirox does not inhibit epimerization of UDP-galactose by purified E. coli GalE; however, ΔgalU, ΔgalE, ΔrfaI, or ΔrfaB mutant strains all have lower ciclopirox minimum inhibitory concentrations than the parent strain. The galU, galE, rfaI, and rfaB genes all encode enzymes that use UDP-galactose or UDP-glucose for galactose metabolism and lipopolysaccharide (LPS) biosynthesis. Indeed, we found that ciclopirox altered LPS composition of an E. coli clinical isolate. Taken together, our data demonstrate that ciclopirox affects galactose metabolism and LPS biosynthesis, two pathways important for bacterial growth and virulence. The lack of any reported fungal resistance to ciclopirox in over twenty years of use in the clinic, its excellent safety profiles, novel target(s), and efficacy, make ciclopirox a promising potential antimicrobial agent to use against multidrug-resistant problematic gram-negative pathogens.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0069646

Cites

87 of 87 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Ciclopirox and ciprofloxacin MICs for E. coli clinical isolates. The left y-axis is the average MIC in µg/ml for ciclopirox (light gray bar) and ciprofloxacin (dark gray bar). The clinical resistance breakpoint for ciprofloxacin is 4 µg/ml and an asterisk indicates isolates with MICs below this breakpoint. MIC measurements were repeated three times, and the average value and standard deviation is shown. The right y-axis denotes the number of antibiotic classes (aminoglycosides, carbapenems, cephalosporins, fluoroquinolones, monobactams, nitrofurans, penicillins, combination penicillins, and sulfamethozazole-trimethoprim) each isolate is resistant to, as indicated by the solid line.
Figure 1 Ciclopirox and ciprofloxacin MICs for E. coli clinical isolates. The left y-axis is the average MIC in µg/ml for ciclopirox (light gray bar) and ciprofloxacin (dark gray bar). The clinical resistance breakpoint for ciprofloxacin is 4 µg/ml and an asterisk indicates isolates with MICs below this breakpoint. MIC measurements were repeated three times, and the average value and standard deviation is shown. The right y-axis denotes the number of antibiotic classes (aminoglycosides, carbapenems, cephalosporins, fluoroquinolones, monobactams, nitrofurans, penicillins, combination penicillins, and sulfamethozazole-trimethoprim) each isolate is resistant to, as indicated by the solid line.CC BY · PubMed Central
Figure 2 Time-kill and growth curves for E. coli with increasing ciclopirox concentrations. ATCC® 25922™ E. coli were grown with the indicated ciclopirox concentrations. (A) Cell densities were measured for three independent cultures by counting the number of colony forming units per 1 ml of culture for 12 hours. (B) The corresponding OD600 of growing cultures were measured over 12 hours. Error bars are the standard deviation from the mean.
Figure 2 Time-kill and growth curves for E. coli with increasing ciclopirox concentrations. ATCC® 25922™ E. coli were grown with the indicated ciclopirox concentrations. (A) Cell densities were measured for three independent cultures by counting the number of colony forming units per 1 ml of culture for 12 hours. (B) The corresponding OD600 of growing cultures were measured over 12 hours. Error bars are the standard deviation from the mean.CC BY · PubMed Central
Figure 3 Effects of metals on exposure to ciclopirox for E. coli. Growth curves measured for three independent cultures of ATCC® 25922™ E. coli grown in (A) LB alone or (B) LB supplemented with 5 µM FeCl3, (C) 50 µM FeCl3, (D) 500 µM ZnCl2, (E) 500 µM MgCl2, (F) or 500 µM NiCl2. Error bars are the standard deviation from the mean.
Figure 3 Effects of metals on exposure to ciclopirox for E. coli. Growth curves measured for three independent cultures of ATCC® 25922™ E. coli grown in (A) LB alone or (B) LB supplemented with 5 µM FeCl3, (C) 50 µM FeCl3, (D) 500 µM ZnCl2, (E) 500 µM MgCl2, (F) or 500 µM NiCl2. Error bars are the standard deviation from the mean.CC BY · PubMed Central
Figure 4 Effects of hydrogen peroxide exposure on bacterial response to ciclopirox. ATCC® 25922™ E. coli were grown to mid-logarithmic phase (OD600 = 0.4) and then subjected to either water or 5 µM H2O2 for 20 minutes. Colony forming units (CFUs) were measured per 1 ml of E. coli grown with either 0, 2.5, 5.0, or 7.5 µg/ml ciclopirox or 1.0 µg/ml chloramphenicol. Each triangle represents a result from an independent culture and the gray bar shows the average. Statistical significance was measured using Student’s t-test.
Figure 4 Effects of hydrogen peroxide exposure on bacterial response to ciclopirox. ATCC® 25922™ E. coli were grown to mid-logarithmic phase (OD600 = 0.4) and then subjected to either water or 5 µM H2O2 for 20 minutes. Colony forming units (CFUs) were measured per 1 ml of E. coli grown with either 0, 2.5, 5.0, or 7.5 µg/ml ciclopirox or 1.0 µg/ml chloramphenicol. Each triangle represents a result from an independent culture and the gray bar shows the average. Statistical significance was measured using Student’s t-test.CC BY · PubMed Central
Figure 5 Effect of GalE on ciclopirox inhibition of bacterial growth. Growth curves for three independent cultures of TransforMax™ EC100™ Electrocompetent E. coli (A) without overexpression plasmid, (B) with empty plasmid pCA24N, or (C) with pCA24N-galE grown with the indicated ciclopirox concentrations. Error bars are the standard deviation from the mean. (D) Schematic representation of GalE epimerization of UDP-galactose to UDP-glucose coupled to the activity of UDP-glucose dehydrogenase (UGD). (E) Using the assay schematized in D, the average rate of NADH formation with or without ciclopirox was measured three independent times per ciclopirox concentration. Error bars are the standard deviation from the mean.
Figure 5 Effect of GalE on ciclopirox inhibition of bacterial growth. Growth curves for three independent cultures of TransforMax™ EC100™ Electrocompetent E. coli (A) without overexpression plasmid, (B) with empty plasmid pCA24N, or (C) with pCA24N-galE grown with the indicated ciclopirox concentrations. Error bars are the standard deviation from the mean. (D) Schematic representation of GalE epimerization of UDP-galactose to UDP-glucose coupled to the activity of UDP-glucose dehydrogenase (UGD). (E) Using the assay schematized in D, the average rate of NADH formation with or without ciclopirox was measured three independent times per ciclopirox concentration. Error bars are the standard deviation from the mean.CC BY · PubMed Central
Figure 6 Effect of ciclopirox on strains involved in the galactose and lipopolysaccharide biosynthesis pathways. (A) Schematic representations of the galactose salvage pathway, (B) LPS biosynthesis pathway proteins for E. coli K-12 strain. Note the O-antigen is not present in K-12 strains, but is depicted for reference for where the O-antigen can attach. Abbreviations include fructose (Fru), glucose (Glc), galactose (Gal), heptose (Hep), N-acetylglucosamine (GlcN), 3-deoxy-d-manno-oct-2-ulopyranosonic acid (Kdo), and phosphate (P). (C) Ciclopirox MICs for Keio parent, BW25113, and single gene Keio deletion strains were measured in three independent cultures. These genes encode enzymes involved in the galactose metabolism and LPS biosynthesis pathways. Student’s t-test was used to assess significance.
Figure 6 Effect of ciclopirox on strains involved in the galactose and lipopolysaccharide biosynthesis pathways. (A) Schematic representations of the galactose salvage pathway, (B) LPS biosynthesis pathway proteins for E. coli K-12 strain. Note the O-antigen is not present in K-12 strains, but is depicted for reference for where the O-antigen can attach. Abbreviations include fructose (Fru), glucose (Glc), galactose (Gal), heptose (Hep), N-acetylglucosamine (GlcN), 3-deoxy-d-manno-oct-2-ulopyranosonic acid (Kdo), and phosphate (P). (C) Ciclopirox MICs for Keio parent, BW25113, and single gene Keio deletion strains were measured in three independent cultures. These genes encode enzymes involved in the galactose metabolism and LPS biosynthesis pathways. Student’s t-test was used to assess significance.CC BY · PubMed Central
Figure 7 Effect of ciclopirox on E. coli LPS structure. LPS was purified from E. coli clinical isolate ATCC®25922™ or K-12 strain MG1655 that had been either incubated with 9 µg/ml ciclopirox as indicated. LPS was subjected to 12.5% Tris-glycine-SDS-PAGE. Lanes 1 and 2 are LPS from two independent LPS purifications. This result was repeated six times with the same results.
Figure 7 Effect of ciclopirox on E. coli LPS structure. LPS was purified from E. coli clinical isolate ATCC®25922™ or K-12 strain MG1655 that had been either incubated with 9 µg/ml ciclopirox as indicated. LPS was subjected to 12.5% Tris-glycine-SDS-PAGE. Lanes 1 and 2 are LPS from two independent LPS purifications. This result was repeated six times with the same results.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 87 references

Cited by

Metadata

Authors
Carlson-Banning, K. M., Chou, A., Liu, Z., Hamill, R. J., Song, Y., & Zechiedrich, L.
Affiliations
  • Baylor College of Medicine (US)
  • Michael E. DeBakey VA Medical Center (US)
Corresponding author
Zechiedrich, Lynn
Venue
PLoS ONE
Published
2013-07-23
Volume
8
Issue
7
Pages
e69646
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2023096091
Cited by
73
References
87
Citations by year
2026: 5 · 2025: 7 · 2024: 3 · 2023: 6 · 2022: 5 · 2021: 12 · 2020: 5 · 2019: 6 · 2018: 7 · 2017: 5 · 2016: 5 · 2015: 6 · 2014: 1
FWCI
1.84
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
Funders
  • National Institutes of Health (NIH T32, NIH-R01, T32 AI55413)
  • National Institute of Allergy and Infectious Diseases (T32 AI55413, R01AI054830, R21AI088123, T32AI055413)
Topics
  • Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
  • Life Sciences › Immunology and Microbiology › Applied Microbiology and Biotechnology › Antimicrobial agents and applications
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Bacterial Genetics and Biotechnology
Keywords
ciclopirox, drug repurposing, antibiotic resistance, Acinetobacter baumannii, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, gales, UDP-glucose 4-epimerase, galactose metabolism, lipopolysaccharide biosynthesis, galU, multidrug-resistant Gram-negative bacteria, minimum inhibitory concentration
MeSH terms
Ciclopirox, Anti-Bacterial Agents, Ciprofloxacin, Drug Resistance, Microbial, Escherichia coli, Galactose, Humans, Hydrogen Peroxide, Iron, Klebsiella pneumoniae, Lipopolysaccharides, Microbial Sensitivity Tests, Mutation, Phenotype, Pyridones, Drug Resistance, Bacterial, Escherichia coli Proteins, Acinetobacter baumannii, Microbial Viability, Biosynthetic Pathways, Drug Repositioning

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.